Fierce Biotech
Novo's CagriSema loses phase 3 battle with Lilly's Zepbound, knocking 15% off share price
Novo Nordisk’s GLP-1/amylin combo has failed to beat Eli Lil | Novo Nordisk’s GLP-1/amylin combo has failed to beat Eli Lilly’s Zepbound in a phase 3 weight loss study, further denting the Danish pharma’s attempts to reclaim its obesity crown.
